Innovating Solutions for Wound & Burn Care

MediWound Ltd.

MediWound Ltd. is a biotechnology niche specialty company focused on developing, manufacturing and globally commercializing innovative products that address unmet needs in the fields of severe burn and chronic wound management.

MediWound’s goal is to provide healthcare professionals and patients with its innovative, burn wound eschar removal agent, NexoBrid™

NexoBrid™ successfully completed clinical development in hospitalized burn wounds and was launched throughout Europe.




MediWound’s innovative drug, NexoBrid™, was approved in December 2012 by EMA via a centralized procedure and was granted orphan indication for removal of eschar in adults with deep partial- and full-thickness thermal burns (also known as debridement)

Read more…